BAJAJ BROKING

Notification
No new Notification messages
Chamunda Electrical Ltd IPO is Open!
Apply for the Chamunda Electrical Ltd IPO through UPI in just minutes.
Q3 FY'25 Results of Top Companies!
From Reliance Industries to TCS to HDFC Bank, check out the latest quarterly results with financial highlights, key performance metrics, and more!
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Alkem Laboratories Launches Kojiglo Serum for Facial Hyperpigmentation

Synopsis:

Alkem Laboratories has launched Kojiglo serum in India for facial hyperpigmentation. The serum, featuring Duo-Lipo technology, enhances skin absorption and efficacy. It includes active ingredients such as liposomal azelaic acid and niacinamide. Alkem Laboratories Ltd. share price closed at ₹5,107.80, up by 1.27 percent.


Alkem Laboratories has launched Kojiglo serum in India, marking a significant expansion in its skincare portfolio. The serum features Duo-Lipo technology, a formulation designed to improve skin absorption and enhance efficacy. It includes active ingredients such as liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide. These components help in reducing facial hyperpigmentation while minimising skin irritation. The serum aims to provide a dermatologically advanced solution for individuals dealing with uneven skin tone and dark spots.

Also read: Godfrey Phillips Faces ₹166 Crore GST Demand, Plans to Appeal

ALKEM LABORATORIES LTD.

Trade

5136.530.60 (0.59 %)

Updated - 05 February 2025
5193.85day high
DAY HIGH
5072.35day low
DAY LOW
50141
VOLUME (BSE)

Key Takeaways

  • Alkem Laboratories has launched Kojiglo serum in India for facial hyperpigmentation.

  • It is the first liposomal serum with Duo-Lipo technology in India.

  • The formula contains azelaic acid, 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.

  • The serum enhances skin absorption and reduces sensitivity risks.

  • Alkem leads the demelanising category with its Kojiglo product line.

  • Kojiglo serum is available only on prescription.

  • Alkem Laboratories Ltd. share price closed at ₹5,107.80, rising by 1.27 percent.

Also read: RVNL Secures ₹404 Crore Project from East Coast Railway

Market Impact and Growth Strategy

Alkem Laboratories has a strong presence in the demelanising category with existing products like Kojiglo cream, Kojiglo face wash, and Kojiglo lotion. According to SMSRC data for October 2024, Kojiglo is the top-prescribed brand in this category by dermatologists. The introduction of Kojiglo serum aligns with the company’s strategy to expand its dermatology segment and strengthen its market share in skincare solutions.

Kojiglo Serum: Key Ingredients and Benefits

Ingredient

Benefit

Liposomal Azelaic Acid

Reduces hyperpigmentation and evens skin tone

Liposomal 4-Butyl Resorcinol

Inhibits melanin production for brighter skin

Tranexamic Acid

Reduces dark spots and prevents pigmentation

Alpha Arbutin

Lightens dark patches and promotes an even skin tone

Niacinamide

Enhances skin barrier and reduces redness

Market Performance and Alkem Laboratories Ltd. Share Price

The launch of Kojiglo serum has further solidified Alkem Laboratories’ position in the skincare industry. Investors responded positively, with Alkem Laboratories Ltd. share price rising by 1.27 percent, closing at ₹5,107.80 on the Bombay Stock Exchange. The company’s strategic focus on dermatology and innovative formulations has contributed to its market growth.

The launch of Kojiglo serum underscores Alkem Laboratories’ commitment to dermatological advancements. With its cutting-edge formulation and prescription-based availability, the product is set to make a mark in the hyperpigmentation treatment segment. Alkem Laboratories Ltd. share price gained traction, reflecting strong investor confidence in the company’s expanding skincare portfolio.

Also read: Lupin Gets Tentative USFDA Nod for HIV Drug, Shares Surge 3

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5300+ Cr MTF Book

icon-with-text